RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial - Ruxo-BEAT

niversity Hospital Aachen AöR, represented by the executive board, represented by the Dean of the Medical Faculty0 个研究点目标入组 380 人开始时间: 2015年2月3日最近更新: 2024年1月8日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 380

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Subjects must provide written informed consent prior to study-specific procedures or assessments which are not routinely performed for diagnosis or monitoring of PV or ET, and the subjects must be willing to comply with treatment and to follow up assessments and procedures
•2.Patient must be 18 years of age or older
•3.Patient´s ECOG performance status must be 0-2
•4.Patient must fulfill WHO 2008 diagnostic criteria for either polycythemia vera (PV) or essential thrombocythemia (ET). Moreover, PV- and ET-patients have to be classified as high risk according to defined criteria as outlined below.
•-For patients with high risk PV OR PV with indication for cytoreductive therapy due to progressive myeloproliferation, AT LEAST ONE of the following must be fulfilled (according to DGHO onkopedia) (Barbui, et al., 2011), (Passamonti, 2009):
•Age > 60 years
•Previous documented thrombosis or thromboembolism
•Platelet count > 1500 x 109/l
•Poor tolerance of phlebotomy or frequent phlebotomy requirement
•Symptomatic or progressive splenomegaly
•Severe disease-related symptoms (according to the investigators definition)
•Progressive leukocytosis with leukocyte count > 20 x 109/l
•-For patients with high risk ET, AT LEAST ONE of the following must be fulfilled (according to DGHO guidelines):
•Age > 60 years
•Platelet count > 1500 x 109/l
•Previous thrombosis or thromboembolism
•Previous severe hemorrhage related to ET (defined as decrease of Hgb of at least 2 g/dl)
•5.Patients must fulfill the following criteria regarding prior therapy:
•PV patients:
•Never treated with cytoreductive drugs except hydroxyurea, anagrelide, or interferon for up to 6 weeks maximum (phlebotomy and/or aspirin are allowed)
•ET patients:
•Naïve and pretreated patients may be entered in this trial.
•6.Patient must have adequate liver function as indicated by a total bilirubin, AST, and ALT = 2 of the institutional upper limit of normal (ULN) value, unless directly attributable to the patient’s MPN
•7.Patient must have a creatinine clearance >40ml/min calculated according to the modified formula of Cockcroft and Gault, eGFR, or directly measured after 24h-urine collection
•8.Patient must be able to swallow and retain oral medication
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 380
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 380

排除标准

•1.Patients who meet criteria for post PV-MF or post ET-MF (IWG-MRT)
•2.Patients who have received previous ruxolitinib treatment
•3.Patients who have a history of anaphylaxis following exposure to the BAT drug of choice
•4.Patients who have an inadequate bone marrow reserve as demonstrated by ANC = 1 x 109/l OR platelet count <50 x 109/l
•5.Patients who have known hepatitis B or C or HIV infection
•6.Patients who suffer from other severe, concurrent diseases, including tuberculosis, serious cardiac functional dysfunction (class III or IV as defined by the New York Heart Association Classification), uncontrolled diabetes, uncontrolled hypertension, severe pulmonary disease (i.e. COPD with hypoxemia), or major organ malfunction that could interfere with the patient’s ability to participate in the study
•7.Patients who have history of active substance or alcohol abuse within the last year
•8.Female patients who are pregnant or nursing
•9.Patients who have participated in another interventional trial and/or used investigational agents or concurrent anticancer treatment for concomitant disease within the last 4 weeks of registration
•10.Any circumstance at the time of study entry that would preclude completion of the study or the required follow-up prohibits inclusion into this study
•11.Subjects who have had an active malignancy during the previous 3 years except for treated cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin, each with no evidence for recurrence in the past 3 years
•12.Patients who have uncontrolled bacterial, viral, or fungal infection
•13.Patients who have any medical condition requiring prolonged use of oral corticosteroids with a dose of more than 20 mg per day (> 1 month)
•14.Patients who have severe cerebral dysfunction and/or legal incapacity
•15.Patients who have had active splanchnic vein thrombosis within the last 3 months (includes Budd-Chiari, portal vein, splenic and mesenteric thrombosis)
•16.Patients who have thyroid dysfunction which is not adequately controlled
•17.Fertile men or women of childbearing potential cannot be included unless they are:
•-surgically sterile or > 2 years after the onset of menopause and/or
•-willing to use a highly effective contraceptive method (Pearl Index <1) such as oral contraceptives, intrauterine device, sexual abstinence, or barrier method of contraception (i.e. condoms) in conjunction with spermicidal jelly during study treatment
•18.Patients who are taking any of the following prohibited medication:
•-clarithromycin, telithromycin, troleandomycin (antibiotics)
•-ritonavir, indinavir, saquinavir, nelfinavir, amprenavir, lopinavir (HIV protease inhibitors)
•-itraconazole, ketoconazole, voriconazole, fluconazole (antifungals)
•19.Patients with a diagnosis of galactose or lactose intolerance or a glucose-galactose-malabsortion

研究者

发起方

niversity Hospital Aachen AöR, represented by the executive board, represented by the Dean of the Medical Faculty

相似试验

进行中（未招募）

1 期

Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEAT Trialpolycythemia vera, essential thrombocythemia

CTIS2024-515619-23-00niversitaetsklinikum Aachen AöR223

已完成

2 期

Efficacy and Safety of Ruxolitinib single treatment in patients with chronic active Epstein-Barr virus infection (Phase II) (investigator-initiated study)chronic active Epstein-Barr virus infection CAEBV

JPRN-UMIN000035121St. Marianna University School of Medicine9

进行中（未招募）

1 期

A Study of Ruxolitinib in Combination With Regorafenib in Subjects Metastatic Colorectal CancerRelapsed or refractory metastatic colorectal cancerMedDRA version: 17.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10010030Term: Colorectal cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2013-004714-18-GBIncyte Corporation420

进行中（未招募）

1 期

EUCTR2013-004714-18-ESIncyte Corporation420

进行中（未招募）

1 期

Treatment with Ruxolitinib in Covid-19 patients with severe symptomsCovid-19 infectionMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862

EUCTR2020-001481-11-DEFriedrich-Schiller-Universität Jena200